<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146426">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075086</url>
  </required_header>
  <id_info>
    <org_study_id>ANGIOSWITCH2011</org_study_id>
    <nct_id>NCT02075086</nct_id>
  </id_info>
  <brief_title>Angiogenic Switch in Patients With Colorectal Cancer</brief_title>
  <acronym>ANGIOSWITCH</acronym>
  <official_title>Angiogenic Switch as Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Hospital de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Hospital de Madrid</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev)
      maintain the same sensitivity after progression to maintenance treatment because they remain
      dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic
      switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev
      chemotherapy combinations .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Days from cycle one day one to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feasibility of doing a clinical prospective trial with a measure od plasma citoquines.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy treatment with Xelox or Xeliri and bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy treatment</intervention_name>
    <description>Xelox or Xeliri Bevacizumab treatment</description>
    <arm_group_label>Chemotherapy treatment</arm_group_label>
    <other_name>Cytokines measure</other_name>
    <other_name>Angiogenic study</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of stage IV colorectal adenocarcinoma.

          -  Age ≥ 18 years .

          -  Measurable disease by RECIST criteria.

          -  Life expectancy ≥ 6 months.

          -  Candidate to receive treatment with first-line chemotherapy.

          -  Availability of tumor tissue.

        Exclusion Criteria:

          -  Patients who have received prior treatment with first-line chemotherapy for
             metastatic disease.

          -  Patients in whom there is contraindication to the administration of either drug used
             in the study: capecitabine, irinotecan, oxaliplatin or Bev.

          -  Patients receiving anticoagulant oral treatment.

          -  Patient with diagnosis of other malignancies within 5 years prior to diagnosis except
             basal cell carcinoma or cervical carcinoma · in situ. · The inclusion of patients
             with malignant disease diagnosed more than 5 years ago without recurrence in the
             previous 3 years will be analyzed individually

          -  Patients with bone disease as the only manifestation of the disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cubillo, MD PhaD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Hospital de Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sofia Perea, MD,PhD</last_name>
    <phone>+34 91 7567850</phone>
    <email>sofiaperea@hospitaldemadrid.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Integral oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia Perea, MD,PhD</last_name>
      <phone>+34 917567850</phone>
      <email>sofiaperea@hospitaldemadrid.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Cubillo, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>November 17, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grupo Hospital de Madrid</investigator_affiliation>
    <investigator_full_name>Sofia Perea, Director Clinical Trials Unit.</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>angiogenic switch</keyword>
  <keyword>plasma cytokines</keyword>
  <keyword>Colon cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
